Key Points
Medpace Holdings, Inc. (MEDP) closed lower, moving from a previous close of $576.49 to $545.36. The stock finished down 5.40% on the session, declining $31.13. The move retraced recent gains and placed shares further below late-November highs, with selling pressure concentrated during the regular session.
Trading occurred on below-average volume, suggesting the decline was driven more by targeted selling than broad-based capitulation. MEDP now sits 13% below its 52-week high of $626.26 set on 11/25/2025. The $550 area has been an active battleground and a psychological marker; failing to hold that zone opens the door to a retest of prior consolidation levels. On the upside, the prior close near $576 and the $585–$600 band represent near-term resistance where supply previously emerged.
In recent sessions, MEDP has shown a tendency to fade strength as buyers meet resistance near the prior highs, a common pattern after a sharp run-up within Health Care. Sector tone has been mixed, with investors balancing defensiveness against valuation sensitivity. Today’s slide fits a market pattern where profit-taking follows significant outperformance, particularly in higher-multiple growth franchises. While the broader Pharmaceuticals, Biotechnology and Life Sciences group remains supported by steady demand drivers, risk management around extended names has been in focus, contributing to range-bound trading for MEDP since late November.
Why Medpace Holdings, Inc. Price is Moving
At a current price of $545.36, Medpace Holdings, Inc. carries a market capitalization of $16.24 billion. The company reports trailing 12-month EPS of $14.30 and is trading 13% below its 52-week high of $626.26. Shares have been active relative to recent weeks, though today’s tape showed below-average volume participation as the stock repriced from recent highs.
The primary catalyst behind today’s move was an institutional block sale. OMERS Administration Corp disclosed via an SEC filing on Dec. 4, 2025 that it reduced its stake in MEDP by 58.91%, creating noticeable supply and pressuring the share price. The transaction followed late-November insider selling, with CEO August J. Troendle having sold 59,025 shares. Fundamentally, Medpace recently posted strong revenue growth of about 23.7% year over year and issued FY 2025 EPS guidance of $14.60 to $14.86. However, sell-side consensus expectations nearer $12.29 and an elevated valuation—roughly a 40.3x P/E multiple—highlight a gap between the company’s growth outlook and what many analysts model. Mixed analyst ratings with a consensus Hold and an average target near $487, roughly 16% below the current price, added to the valuation overhang.
In short, today’s decline reflects profit-taking by large holders layered onto a premium multiple and tempered Street expectations. For investors, the setup underscores how institutional flows can dominate near-term price action when a high-quality, higher-multiple Health Care name trades near historic highs and then meets incremental supply.
What is the Medpace Holdings, Inc. Rating - Should I Sell or Buy?
Weiss Ratings assigns MEDP a B rating. Current recommendation is Buy.
The rating is built on five indices: the Excellent Growth Index (measures revenue and earnings expansion), supported by approximately 23.74% revenue growth; the Excellent Efficiency Index (assesses operational effectiveness), reflected in an 18.36% profit margin and a robust 73.70% ROE; the Excellent Solvency Index (evaluates balance sheet health and debt management), indicating strong financial flexibility; the Good Total Return Index (captures stock price gains plus dividends), recognizing MEDP’s solid multi-period performance even without a dividend contribution; and the Fair Volatility Index (measures price stability and risk), acknowledging episodic drawdowns like today’s move. The 40.30 P/E ratio signals a growth premium that is consistent with a B-rated profile when paired with strong fundamentals.
Relative to sector peers, MEDP’s B rating aligns with Eli Lilly (LLY, B) and Johnson & Johnson (JNJ, B), while topping AbbVie (ABBV, C). This places Medpace among quality Health Care names from a risk-adjusted standpoint, though its business model and size differ from mega-cap peers.
Overall, the B rating reflects a favorable balance of growth, efficiency, and solvency against valuation and volatility considerations. Strength across the growth, efficiency, and solvency dimensions outweighs the risks implied by a premium multiple and occasional price swings. Within the Weiss framework, that mix supports a Buy recommendation for MEDP, recognizing that near-term fluctuations can occur even in fundamentally strong, B-rated Health Care stocks.
About Medpace Holdings, Inc.
Medpace Holdings, Inc. is a full-service contract research organization (CRO) that partners with biopharmaceutical and medical device companies to design and run clinical trials. Operating within the Health Care sector and the Pharmaceuticals, Biotechnology and Life Sciences industry, Medpace supports drug and device development from early-stage clinical work through post-approval studies. The company was founded in 1992 by Dr. August J. Troendle and is headquartered in Cincinnati, Ohio, with a global footprint across North America, Europe, Asia, and other regions to support multinational clinical programs.
Medpace’s integrated services span Phase I–IV clinical trial management, including protocol design, site selection, patient recruitment, clinical monitoring, and project management. The firm provides regulatory affairs expertise, medical writing, biostatistics, data management, and pharmacovigilance. It also operates central laboratories and imaging core labs to deliver biomarkers, bioanalytical testing, and imaging endpoints under a unified quality framework. Therapeutic strengths include oncology, cardiology and metabolic disease, infectious disease and vaccines, central nervous system disorders, and rare diseases, enabling specialized trial designs and execution.
The company’s model emphasizes a full-service, in-house approach with cross-functional teams, therapeutic expertise, and standardized processes intended to reduce cycle times and improve data quality. A global site network, operational discipline, and centralized labs allow consistent execution across geographies. Medpace serves a diverse client base ranging from emerging biotechnology firms to large pharmaceutical companies, with an emphasis on collaboration and end-to-end accountability. This integrated platform and therapeutic depth position Medpace as a differentiated provider within the CRO landscape focused on high-complexity, high-value clinical development programs.
Investor Outlook
With a Weiss B (Buy) rating, investors watching MEDP should monitor whether the $550 area stabilizes and how institutional flows evolve following recent block sales. Valuation versus growth delivery remains central, alongside sector trends in Pharmaceuticals, Biotechnology and Life Sciences. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.